Document is current

Article History

Received: 10 October 2017

Revised: 23 November 2017

Accepted: 30 November 2017

First Online: 2 May 2018

Compliance with ethical standards

:

: HL has received speakers’ honoraria from Celgene, Amgen, Takeda, Janssen, and Bristol-Myers Squibb, and research funding from Takeda and Amgen, as well as consultancy fees from Amgen, Takeda, and Janssen. MD has received speakers’ honoraria and consultancy fees from Amgen, Takeda, Janssen, Celgene, and Bristol-Myers Squibb, as well as research support from Celgene and Janssen. TF has received speakers’ honoraria and honoraria for participation in advisory boards from Celgene, Janssen, Takeda, Amgen, and PharmaMar. HE has received speakers’ honoraria and honoraria for participation in advisory boards for Celgene, Janssen, Amgen, Bristol-Myers Squibb, and Novartis, and consultancy fees or honoraria from Celgene, Janssen, Bristol-Myers Squibb, and Amgen. FG has received honoraria from Amgen, Bristol-Myers Squibb, Celgene, and Takeda, and honoraria for participation in advisory boards from Janssen, Amgen, Celgene, Roche, and Takeda. PM has received honoraria from Novartis, Janssen, Celgene, Millennium, Onyx, and Bristol-Myers Squibb, and consultancy fees from Novartis, Janssen, Celgene, Millennium, and Onyx. HA-L has received honoraria for participation in advisory boards from Celgene, Janssen, Amgen, and Sanofi, and research funding from Celgene and Sanofi. RH has received consultancy fees, research funding, and honoraria for participation in advisory boards from Amgen, Takeda, Bristol-Myers Squibb, Celgene, Novartis, and Janssen. MM has received honoraria and research funding from Janssen, Celgene, Amgen, Takeda, Novartis, and Bristol-Myers Squibb. MC has received consultancy fees from Janssen, Celgene, Amgen, and Bristol-Myers Squibb, speakers’ honoraria from Janssen, Celgene, Amgen, and Takeda, honoraria for participation in advisory boards from Janssen, Celgene, Takeda, Amgen, and Bristol-Myers Squibb, as well as honoraria from Janssen, Celgene, Bristol-Myers Squibb, Amgen, Novartis, and Takeda. MAD has received consultancy fees and honoraria from Celgene, Onyx, Janssen, Novartis, and Amgen, and honoraria for participation in advisory boards from Amgen, Takeda, Celgene, and Janssen. JS-M has received speaker’s honoraria and consultancy fees from Takeda, Celgene, Novartis, Amgen, Janssen, Bristol-Myers Squibb, Sanofi, and MSD. ET has received honoraria from Janssen, Amgen, Takeda, Abbvie, Bristol-Myers Squibb, PharmaMar, and Celgene, research funding from Amgen, Genesis, Janssen, Novartis, and Takeda, honoraria for participation in advisory boards from Takeda, as well as honoraria for participation in the data monitoring committee from Celgene. SZ has received honoraria for participating in advisory boards and research funding from Janssen, Celgene, Novartis, and Takeda. M-VM has has received personal fees from Janssen, Celgene, BMS, Amgen, and Takeda. GC has received consultancy fees and research funding from Janssen, Celgene, Takeda, Sanofi, Amgen, and Bristol-Myers Squibb. XL has received honoraria for participating in advisory boards and honoraria from Celgene, Janssen, Takeda, Amgen, Novartis, Sanofi, BMS, Merck, Pierre Fabre, and Gilead. HG has received research funding and honoraria from Celgene, Chugai, Novartis, Janssen, and Bristol-Myers Squibb, and honoraria for participating in advisory boards from Janssen, Celgene, Novartis, Amgen, Takeda, and Bristol-Myers Squibb. GJ has received speakers’ honoraria and honoraria for participating in advisory boards from Takeda, Celgene, Janssen, Amgen, and Roche, and research funding from Onyx, Celgene, and CRUK. MK received research funding from Celgene, and honoraria for participating in advisory boards from Takeda, Celgene, Amgen, Janssen, and Bristol-Myers Squibb. KW has received honoraria from Novartis, Janssen, Celgene, Amgen, Onyx, Takeda, and Bristol-Myers Squibb, and consultancy fees from Janssen, Celgene, Amgen, Bristol-Myers Squibb, Takeda, and Onyx. NvdD has received research funding and honoraria for participating in advisory boards from Janssen, Celgene, Bristol-Myers Squibb, and Amgen. AW has received research support from Amgen and Celgene, and honoraria for participation in advisory boards from Amgen, Celgene, and Takeda. MB has received honoraria for participating in advisory boards from Novartis, Amgen, Celgene, and Janssen, and speakers’ honoraria from Amgen, Celgene, and Janssen. U-HM has received honoraria for participating in advisory boards from Amgen and Takeda, and honoraria from Amgen, Celgene, Takeda, Mundipharma, Janssen, and Novartis. PS has received honoraria for participating in advisory boards and honoraria from Celgene, Janssen, Amgen, Karyopharm, and Takeda. MB, JC, CD, ME, and LG declare that they have no conflict of interest.